Study patients
| Disease phase . | No. . |
|---|---|
| Chronic (early/late) | 148 (118/30) |
| Accelerated | 25 |
| Blastic | 11 |
| Characteristics of patients with chronic phase CML, % | |
| Age at least 60 years | 17 |
| Spleen at least 10 cm below costal margin | 10 |
| White blood cell count at least 30 × 109/L | 57 |
| Platelet count at least 700 × 109/L | 17 |
| Peripheral blasts at least 3% | 11 |
| Marrow blasts at least 5% | 5 |
| Peripheral basophils at least 7% | 17 |
| Marrow basophils at least 3% | 25 |
| Predictors of shorter survival of patients with chronic phase CML (univariate analysis), P | |
| VEGF level | .008 |
| Risk-group assignment | .01 |
| Age | .1 |
| Spleen size | .2 |
| White blood cell count | .9 |
| Platelet count | .002 |
| Hemoglobin level | .9 |
| Percentage of peripheral basophils | .1 |
| Disease phase . | No. . |
|---|---|
| Chronic (early/late) | 148 (118/30) |
| Accelerated | 25 |
| Blastic | 11 |
| Characteristics of patients with chronic phase CML, % | |
| Age at least 60 years | 17 |
| Spleen at least 10 cm below costal margin | 10 |
| White blood cell count at least 30 × 109/L | 57 |
| Platelet count at least 700 × 109/L | 17 |
| Peripheral blasts at least 3% | 11 |
| Marrow blasts at least 5% | 5 |
| Peripheral basophils at least 7% | 17 |
| Marrow basophils at least 3% | 25 |
| Predictors of shorter survival of patients with chronic phase CML (univariate analysis), P | |
| VEGF level | .008 |
| Risk-group assignment | .01 |
| Age | .1 |
| Spleen size | .2 |
| White blood cell count | .9 |
| Platelet count | .002 |
| Hemoglobin level | .9 |
| Percentage of peripheral basophils | .1 |
CML indicates chronic myeloid leukemia; VEGF, vascular endothelial growth factor.